103 results about "Lower urinary tract symptoms" patented technology

The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and / or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and / or painful bladder syndrome and / or bladder pain syndrome.

Systems for and methods of assessing lower urinary tract function from urinary flow data via sound analysis and user-provided information regarding the lower urinary tract symptoms (LUTS) of frequency, urgency and urge incontinence. Embodiments of the LUTS assessment systems include a computer and a telephone or a digital recording mechanism to capture the sound of one or more urination events, which are stored as audio files in a database. The LUTS assessment systems may include sound analysis software for analyzing the strength and duration of each urination event and may include a web-based software application for viewing the results via the Internet or other network. The database stores information from multiple urination events, and combined with information regarding the lower urinary tract symptoms, serves as an objective tool to assess bladder function and monitor progression of disease or therapy effectiveness.

The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and / or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and / or painful bladder syndrome and / or bladder pain syndrome.

The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and / or a lower urinary tract symptom (LUTS) associated with chronic prostatitis and / or chronic pelvic pain syndrome.

The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.

The use of PDE 5 inhibitors in methods for the treatment of benign prostatic hyperplasia or lower urinary tract symptoms and other physiological disorders, as a monotherapy and in combination with other active agents is disclosed. For example, a representative compound useful in the methods of the invention is:

Systems for and methods of assessing lower urinary tract function from urinary flow data via sound analysis and user-provided information regarding the lower urinary tract symptoms (LUTS) of frequency, urgency and urge incontinence. Embodiments of the LUTS assessment systems include a computer and a telephone or a digital recording mechanism to capture the sound of one or more urination events, which are stored as audio files in a database. The LUTS assessment systems may include sound analysis software for analyzing the strength and duration of each urination event and may include a web-based software application for viewing the results via the Internet or other network. The database stores information from multiple urination events, and combined with information regarding the lower urinary tract symptoms, serves as an objective tool to assess bladder function and monitor progression of disease or therapy effectiveness.

Disclosed is a sulfonamide compound having a chemical structure characterized in that the compound has an amide structure wherein a carbon atom in the amide binds to a nitrogen atom in a sulfonamide through a lower alkylene, or a salt of the compound. The compound or the salt has a potent antagonistic activity against an EP1 receptor and is therefore useful as a therapeutic agent for a disease associated with an EP1 receptor, particularly lower urinary tract symptom.

A method of diagnosing and treating a patient having lower urinary tract symptoms caused by insufficient blood flow to the urinary bladder, the urethra, a nerve innervating the urinary bladder, or a nerve innervating the urethra due to atherosclerosis of a pelvic artery is disclosed. A method of diagnosing the patient's condition includes determining if a stenosis exists within a pelvic vessel. A method of treating the patient's condition may include placing a stent within the stenosed pelvic artery.

[Object] A compound which is useful as an EP1 receptor antagonist is provided.[Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and / or treating a lower urinary tract symptom or the like.

Methods for ameliorating the effects of benign prostate hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene, about 0.25% to 2% by weight of phytoene, and about 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising β-carotene, γ-carotene, and δ-carotene, a phytosterol, a tocopheral and a phospholipid. Use of multi-carotenoids compositions for the treatment of urinary tract malfunctions including benign prostate hyperplasia and lower urinary tract symptoms.